Program of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicenter, randomized controlled study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Febuxostat (Primary)
- Indications Hyperuricaemia
- Focus Pharmacodynamics
- Acronyms PRIZE
- 01 Aug 2018 Planned End Date changed from 31 Jul 2018 to 31 Aug 2018.
- 26 Jul 2016 Planned End Date changed from 31 Mar 2018 to 31 Jul 2018.
- 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.